STRATA Skin Sciences

STRATA Skin Sciences, Inc. is a medical technology company in Dermatology and Plastic Surgery. It engages in developing, commercializing and marketing products for the treatment of dermatologic conditions. The firm operates through the following segments: Dermatology Recurring Procedures and Dermatology Procedures Equipment. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. The Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. The company was founded by Dina Gutkowicz-Krusin in December 1989 and is headquartered in Horsham, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

STRATA Skin Sciences pursues growth through international expansion and profitability

STRATA Skin Sciences is strategically focusing on increasing revenue per device and expanding internationally to drive growth.
While facing challenges in domestic billings and lower revenue, the company's cost-cutting measures are enhancing profitability.
The company's efforts to optimize operations and drive revenue growth position it well for future success.

STRATA Skin Sciences reports revenue growth and operational improvements in Q2 2024

STRATA Skin Sciences (SSKN) delivered a mixed performance in Q2 2024 with revenue growth, improved operational efficiency, and strategic financing.
The company showcased strengths in equipment revenue growth, expanding customer base, and effective cost management strategies.
Challenges remain in achieving profitability, sustaining growth momentum, and managing operational costs effectively.
Opportunities lie in leveraging marketing efforts, expanding product offerings, exploring new markets, and optimizing operational efficiency for future growth.

STRATA Skin Sciences reports solid Q3 performance with growth opportunities

STRATA Skin Sciences demonstrated solid financial performance in Q3 2024, leveraging improved revenue per XTRAC and cost management.
While facing challenges in device adoption and operating expenses, the company's DTC initiatives and cash position present growth opportunities.
By focusing on enhancing device utilization and investing in innovation, STRATA Skin Sciences can drive future revenue growth and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

HORSHAM, Pa., Nov.  19, 2019  (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN) (“STRATA” or the “Company”), a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced that it has been notified by Nasdaq that STRATA has regained compliance with  the Nasdaq listing requirements as required by Rule 5150(c)(1), the scheduled hearing before the Nasdaq Hearings Panel has been cancelled and the Company will continue to trade on Nasdaq.  

STRATA Skin Sciences, Inc. Announces Compliance with Nasdaq Listing Rules

HORSHAM, Pa., Nov.  14, 2019  (GLOBE NEWSWIRE) -- STRATA Skin Sciences (NASDAQ: SSKN) (“STRATA”) a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced that Dr. Dolev Rafaeli, STRATA’s Chief Executive Officer, will present a corporate overview at the  13th Annual Canaccord Genuity Medical Technologies & Diagnostics Forum at the Westin Grand Central Hotel in New York City on Thursday, November 21st  at 10:30 am Eastern Time.

STRATA Skin Sciences to Participate in the 13th Annual Canaccord Genuity Medical Technologies & Diagnostics Forum

STRATA Skin Sciences, Inc.'s (SSKN) CEO Dolev Rafaeli Hosts Business Update Call (Transcript)

Company filed its Annual Report on Form 10-K for the year ended December 31, 2018

STRATA Skin Sciences Receives Extension to Stay of Suspension from NASDAQ Listing

HORSHAM, Pa., Oct.  07, 2019  (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (Nasdaq: SSKN) (“STRATA” or the “Company”), a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announced today that it had received written notification from The Nasdaq Stock Market LLC (“Nasdaq”) on October 1, 2019 notifying the Company that it would be subject to delisting unless the Company timely requested a hearing before a Nasdaq Hearings Panel (the “Panel”). Accordingly, the Company timely requested a hearing earlier today. The hearing request automatically stayed any delisting or suspension action through October 22, 2019. Pursuant to the Nasdaq Listing Rules, the hearing request included a request to the Panel that the stay be extended through the hearing date and the expiration of any extension period granted by the Panel following the hearing. In the event the Company becomes current in the filing of its periodic reports prior to the hearing, the hearing can be canceled. Hearings are typically scheduled to occur approximately 30 to 45 days after the date of the hearing request. The Company will make a further announcement following the Panel’s decision on the request for an extended stay.

Strata Skin Sciences Receives Nasdaq Notice of Non-compliance

HORSHAM, Pa., Sept.  10, 2019  (GLOBE NEWSWIRE) -- STRATA Skin Sciences (NASDAQ: SSKN) (“STRATA”) a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced that Dr. Dolev Rafaeli, STRATA’s Chief Executive Officer, will present a corporate overview at the Ladenburg Thalmann 2019 Healthcare Conference at the Sofitel Hotel in New York, on Tuesday, September 24th at 11:30 am Eastern Time.

STRATA Skin Sciences to Participate in Ladenburg Thalmann 2019 Healthcare Conference

HORSHAM, Pa., Aug.  28, 2019  (GLOBE NEWSWIRE) -- STRATA Skin Sciences (NASDAQ: SSKN) (“STRATA”) a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced that Dr. Dolev Rafaeli, STRATA’s Chief Executive Officer, will present a corporate overview at the H. C. Wainwright Annual Healthcare Conference at the Lotte New York Palace Hotel, on Monday, September 9th at 3:25 pm Eastern Time.

STRATA Skin Sciences to Participate in H.C. Wainwright’s Annual Healthcare Conference

Strata Skin (SSKN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Strata Skin (SSKN) Report Negative Q4 Earnings? What You Should Know

News for STRATA Skin Sciences Stock (SSKN)